National Institute of Neurological Disorders and Stroke (NINDS)
National Institutes of Health Clinical Center (CC)
Primary Purpose: Treatment
Reduction in mean number of new gaolinium-enhancing lesions in the treatment phase (Weeks 18 to 30) versus baseline (Weeks -12 to 0).
Mean change in the MS functional composite from completion of treatment. Reduction of mean number of new gaolinium-enhancing lesions at the completion of treatment. Mean change in Multiple Sclerosis Quality of Life Inventory from completion of t...
18 Years to 65 Years (Adult)
October 30, 2003
October 4, 2007
August 16, 2011
November 3, 2003
July 2, 2017
National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States
† Study has passed its completion date and status has not been verified in more than two years.